Irvine Scientific Launches BalanCD(TM) CHO SLX A Culture Media Developed for the Selexis SURE CHO-M Cell Line
GENEVA, June 6, 2012 /PRNewswire/ — Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the launch and availability of a chemically-defined, animal-component free media designed to greatly increase the productivity and viability of Selexis SURE CHO-M cell lines. This product, developed in collaboration with Irvine Scientific is designed exclusively for Selexis. The new formulation is called BalanCD(TM) CHO SLX A, improves cell viability, increases productivity during pilot and process development, and maintains consistency between runs. These and other benefits should facilitate scale-up in bioreactors.
Irvine Scientific, using its Rational Culture Media Design(TM) approach, worked with researchers at Selexis to develop a custom formulation that allows rapid optimization of processes where the SUREtechnology Platform(TM) is being evaluated or used.
“Our customers will be very satisfied with the outcome of this collaboration with Irvine Scientific, a company known for innovative, high production CHO formulations,” said Igor Fisch, PhD, CEO of Selexis SA. “In combination with our SUREtechnology(TM) Platform, BalanCD(TM) CHO SLX A is an important new resource to further assist our customers in speeding drug development while reducing production costs and risks.”
“We are very pleased to be able to offer an optimized media for the Selexis SUREtechnology(TM) Platform, an industry standard for cell line development,” said Jessie Ni, PhD, CSO of Irvine Scientific. “BalanCD(TM) CHO SLX A represents an important expansion of Irvine Scientific’s portfolio of chemically-defined media. But more importantly provides a more complete solution to customers that need to increase the speed with which they evaluate cell lines, the quality of proteins developed, and optimization of process development. The collaboration with Selexis can provide all these benefits to customers using CHO platforms for their protein therapeutics.”
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform(TM) is based on Selexis Genetic Elements(TM) — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform(TM) to be launched in 2012.
About Irvine Scientific
Irvine Scientific, a member of JX Holdings group, is a worldwide leader in the design, manufacture and distribution of medical devices, including Industrial Cell Culture, Cytogenetic, Assisted Reproductive Technology (ART) and Specialty Media products. Irvine Scientific is a worldwide media provider that is regulated and adheres to both ISO and FDA regulations with dual manufacturing facilities in California, USA and Tokyo, Japan. Irvine Scientific is a large scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets. The company’s extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II / III medical devices, industrial scale manufacturing capacity, provides its customers with unique capabilities and support. Irvine Scientific delivers products worldwide to biopharmaceutical industry, research and medical laboratory communities.
For more information:
- Visit http://www.irvinesci.com
- Follow us on LinkedIn at http://www.linkedin.com/company/irvine-scientific?trk=tabs_biz_home
Contact: Robert Meister, +1-602-953-1716, email@example.com
SOURCE Selexis SA